of 45
7/25/2019 Nephrotic Syndrome 2016
1/45
Nephrotic Syndrome
Abdulrahman Mashi
7/25/2019 Nephrotic Syndrome 2016
2/45
Nephrotic Syndrome
Nephrotic-range proteinuria : urine proteinexcretion of >3.5 g!" h or a urine protein-
creatinine ratio of >35## mgg in a $spot$morning urine sample
%ypoalbuminemia &serum albumin' 3 gd().
*demaHyperlipidemia
7/25/2019 Nephrotic Syndrome 2016
3/45
+athogenesis
Underfll
Model
Overfll
Model
Permeability of glom.cap.memb. Proteinuria
Intravascular vol
ADHRenal perfusion
pressure
Water
Reabsorptn
InCollectingducts
Actv. reinin
Ang. ald. sys
Tubular reabsorp.
Of a
Hypoalbuminemia
Hepatic protein synt!esis
Plasma oncotic
pressure
HyperlipidemiaTransudation of fluid
from intravascular
comp. To interstial
space
"dema
7/25/2019 Nephrotic Syndrome 2016
4/45
*le,ated lipids occur from a combinationof
increased hepatic apolipoprotein
synthesis in response to a lo plasmaoncotic pressure
decreased acti,ity of ey en/ymes suchas lipoprotein lipase and lecithin-cholesterol acyltransferase.
7/25/2019 Nephrotic Syndrome 2016
5/45
Nephrotic Syndrome
NephroticSyndrom
e
+rimary&0diopathic)
Secondary
7/25/2019 Nephrotic Syndrome 2016
6/45
Nephrotic Syndrome
Primary (idiopathic)Minimal change disease &M12)
Membranous nephropathy &MN)
ocal segmental glomerulosclerosis &S4S).
Mesangiocapillary &Membranoproliferati,e) 4N&M14N M+4N)
ibrillary glomerulopathy : may be assocaited emalignacy
Immunotactoid glomerulopathy : May beassociated with chronic lymphocytic leukemia or Bcelllymphomas
7/25/2019 Nephrotic Syndrome 2016
7/45
Nephrotic Syndrome
Secondary
2iabetes &the most common)
0nfections
2rugs
Autoimmune diseases
Amyloidosis
Monoclonal immunoglobulin depositiondisease
7/25/2019 Nephrotic Syndrome 2016
8/45
Nephrotic Syndrome
Important pointsMinimal change glomerulopathyis the most common cause of thenephrotic syndrome in children
Membranous glomerulopathy and !S"S are the most common
causes of idiopathic nephrotic syndrome in adults.
Membranous glomerulopathy is the most common orldide
!S"Sis the most common in S and no increasing to be the mostcommon orldide
!S"Sis the most common cause in blac personsMembranous glomerulopathyis the most common cause in hitepersons
Membranous glomerulopathy has the highest predilection forrenal #ein thrombosis among all causes of the nephrotic syndrome
7/25/2019 Nephrotic Syndrome 2016
9/45
*,aluation
7/25/2019 Nephrotic Syndrome 2016
10/45
6reatment
4eneral measures: *le,ated lipid le,els are typically
treated ith statin medications
+rophylactic anticoagulation : 0n any type of Nephrotic if albumin le,el
7!.# gd( &!# g() ith lo bleeding risregardless of cause.
0n patients ith membranousglomerulopathy ith lo ris for bleedinghas been if albumin 7!.8 gd( &!8 g().
7/25/2019 Nephrotic Syndrome 2016
11/45
6reatment
4eneral measures: *dema is treated ith a lo salt diet
and loop diuretics &alone or in
combination ith a thia/ide andpotassium-sparing diuretics).
A1* and A; to reduce proteinurea
Maintain good nutrition6reatment of underlying cause
7/25/2019 Nephrotic Syndrome 2016
12/45
1omplications
7/25/2019 Nephrotic Syndrome 2016
13/45
7/25/2019 Nephrotic Syndrome 2016
14/45
7/25/2019 Nephrotic Syndrome 2016
15/45
S4S
1auses: 0diopathic : Some cases of idiopathic S4S are thought to
be related to a circulating plasma factor because a signi
7/25/2019 Nephrotic Syndrome 2016
16/45
S4S
!i#e subtypes
not otherise speci
7/25/2019 Nephrotic Syndrome 2016
17/45
S4S
linical Mani%estations :
*ither asymptomatic proteinuria or edema.
More than to thirds of patients are fully
nephrotic at presentation Subnephrotic proteinuria may occur
especially ith secondary S4S fromhyper
7/25/2019 Nephrotic Syndrome 2016
18/45
S4S
iagnosis
6he hallmar of S4S is the presence ofsegmental scars in some glomeruli.
*lectron microscopy shos ,isceralepithelial cell %oot process e*acement
no immune deposits+
7/25/2019 Nephrotic Syndrome 2016
19/45
-reatment and Prognosis
0n idiopathic S4S only a minority of patients
experience a spontaneous remission.
-here%ore& treatment is indicated in mostpatients+
6herapy is usually ith glucocorticoids or calcineurininhibitors both at the time of initial presentation andfor relapsing disease.
A complete or partial remission may be seen in up to"#B to C#B of patients using these treatments.
S4S recurs in the transplanted idney in 3#B or more
of cases.
7/25/2019 Nephrotic Syndrome 2016
20/45
0n secondary S4S caused by infection ordrugs treatment of the infection or remo,alof the oDending agent may halt progressionof the disease and impro,e symptoms.
0n obese patients ith liely secondaryS4S eight loss is sometimes associatedith a drop in proteinuria as is the use ofA1* inhibitors or angiotensin receptorblocers &A;s) and is the preferred initialtherapy.
7/25/2019 Nephrotic Syndrome 2016
21/45
Membranous 4lomerulopathy
Primary or secondary
Primary %orm &most commonorldide): antiphospholipaseA!receptor autoantibodies can be
found in E5B of cases lead to
acti,ation of complement anddamage the 4;M.
7/25/2019 Nephrotic Syndrome 2016
22/45
Membranous 4lomerulopathy
May be associated with or secondary to:
S(*
0nfections: hepatitis ; and 1 ,irus infectionsF syphilisF
malaria Medication exposure: penicillamineF NSA02sF 6N-G
inhibitorsF tiopronin
Mercury or gold exposure
Malignancies: Solid organ Malignancy &bladderbreast colon lung pancreas prostate stomachcarcinoma)F carcinoidF sarcomasF lymphomasFleuemias
6hyroid disease
7/25/2019 Nephrotic Syndrome 2016
23/45
1linical Manifestations
(ie other causes of the nephroticsyndrome &edema hypertensionmicrohematuria) but the propensity to
thromboembolic e,ents &particularlyrenal ,ein thrombosis) is much higher.
Secondary causes should be soughtparticularly occult malignancy in olderpatients.
7/25/2019 Nephrotic Syndrome 2016
24/45
Membranous4lomerulopathy
iagnosis
(ight microscopy shos glomerular capillaryloops that often appear thicened ithout
any proliferati,e lesions.0mmuno@uorescence and electronmicroscopy sho subepithelial immunedense deposits.
.here a#ailable& P/012 antibodies
should be measured+
7/25/2019 Nephrotic Syndrome 2016
25/45
6reatment
p to one third of patients ith idiopathic M4 remitspontaneously in C to H! months.
1onser,ati,e management is appropriate during
this period.
0n patients ith idiopathic M4 who ha#epersistent disease a%ter 3 to 41 months or
who ha#e worsening kidney %unction or athromboembolic e#ent®imens containingalternating glucocorticoids ith cyclophosphamideor calcineurin inhibitors &cyclosporine or tacrolimus)may be used.
7/25/2019 Nephrotic Syndrome 2016
26/45
6reatment
Ither options for relapsing or refractorydisease include mycophenolate mofetil
adrenocorticotropic hormone and theantiJ;-cell antibody rituximab.
or secondary causes of M4 treat theunderlying cause lie treatment ofhepatitis ; ,irus infection ith anti,iralagents
7/25/2019 Nephrotic Syndrome 2016
27/45
7/25/2019 Nephrotic Syndrome 2016
28/45
7/25/2019 Nephrotic Syndrome 2016
29/45
Minimal 1hange 4lomerulopathy
Primary %orm &0diopathic)
secondary : Medications &such as NSA02s lithium
pamidronate rifampin and the interferons) Malignancies &such as %odgin
lymphoma other lymphoproliferati,edisorders and thymoma)
0nfections: 0nfectious Mononucleosis and 6;
7/25/2019 Nephrotic Syndrome 2016
30/45
linical Mani%estations
+atients ith M14 typically presentith acute onset of edema andeight gain due to @uid retention.
rine protein le,els tend to besigni
7/25/2019 Nephrotic Syndrome 2016
31/45
M12
iagnosis
Normal glomeruli on both light andimmuno@uorescence microscopy.
6he tubules may sho lipid accumulation.
6n electron microscopy& the "BM isnormal with e'tensi#e e*acement o%
#isceral epithelial %oot processes+
7/25/2019 Nephrotic Syndrome 2016
32/45
6reatment
+atients typically respond to glucocorticoids &Hmggd or!mgg e,ery other day )ithin 8 to HC ees.
1omplete remission achie,ed in around E# B
elapse is common and in up to "#B of patients thecourse of M14 is one of remission folloed by relapse.
or freKuently relapsing or glucocorticoid-dependent
disease treatment options include cyclophosphamidecalcineurin inhibitors &tacrolimus or cyclosporine)mycophenolate mofetil and rituximab.
7/25/2019 Nephrotic Syndrome 2016
33/45
7/25/2019 Nephrotic Syndrome 2016
34/45
2iabetic Nephropathy
2iabetic nephropathy &2N) is theleading cause of *SL2 in the nitedStates
6he strongest clinical indicator forprogressi,e idney disease is the
le,el of urine albumin.
7/25/2019 Nephrotic Syndrome 2016
35/45
2isk %actors %or de#eloping N
older age
race &American 0ndian Mexican American
and blac)poor glycemic control
hypertension
cigarette smoingfamily history of idney disease
7/25/2019 Nephrotic Syndrome 2016
36/45
7/25/2019 Nephrotic Syndrome 2016
37/45
linical Mani%estations
Moderately increased albuminuria &formerly nonas microalbuminuria) de
7/25/2019 Nephrotic Syndrome 2016
38/45
iagnosis
Annual testing for albuminuria should begin at
the time of diagnosis in type ! diabetes and 5years after diagnosis in type H diabetes.
Lidney biopsy is not indicated unless there isa suspicion of another glomerular disease.
In electron microscopy the 4;M is normalith extensi,e eDacement of ,isceralepithelial foot processes.
Moderately increased albuminuria de
7/25/2019 Nephrotic Syndrome 2016
39/45
Indications %or kidney biopsy
acute onset of the nephrotic syndrome
7/25/2019 Nephrotic Syndrome 2016
40/45
+athology
2N aDects e,ery compartment of the idney.
0n the glomerulus there is e'pansion o% themesangium and thickening o% the basementmembrane folloed by focal &nodular) sclerosis&the Limmelstiel-ilson lesion) then globalsclerosis of the glomerulus.
0nterstitial
7/25/2019 Nephrotic Syndrome 2016
41/45
6reatment
Achie,ing targets of glycemic control&hemoglobin AHc'EB) and blood
pressure &'H"## mm %g.
0n patients ho ha,e diabetes ithmoderately increased albuminuria or
se,erely increased albuminuria A1*inhibitors or A;s ha,e been shon toslo progression.
7/25/2019 Nephrotic Syndrome 2016
42/45
ead about
M+4N
Amylodosis
Multiple Myloma
%0 associated nephropathy
%epatitis ; associated idney disease
7/25/2019 Nephrotic Syndrome 2016
43/45
7/25/2019 Nephrotic Syndrome 2016
44/45
eferences
7/25/2019 Nephrotic Syndrome 2016
45/45